Sep 26 |
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference
|
Sep 16 |
RVPH: RECOVER Biomarker KOL Event
|
Sep 9 |
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
|
Sep 4 |
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
Aug 27 |
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
|
Aug 26 |
RVPH: August OLE Update
|
Aug 21 |
Reviva Pharmaceuticals stock falls after it prices $5M offering
|
Aug 21 |
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules
|
Aug 15 |
Reviva Pharmaceuticals GAAP EPS of -$0.26
|
Aug 14 |
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|